Ascendis Pharma A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASND research report →
Range $268 – $352
Price Chart
About the company
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
- CEO
- Jan Moller Mikkelsen
- IPO
- 2015
- Employees
- 1,189
- HQ
- Hellerup, CR, DK
AI snapshot
Six angles, distilled from the data.
The stock is in a strong multi-month uptrend and remains above its 200-day average, with price still near the 52-week high rather than the low. That keeps the regime constructive, though the recent advance leaves less room for error after a sharp run.
Wall Street stays constructive: 24 buys and 2 holds support a Buy consensus, with the average target at 314.14 versus the last close at 267.07. Recent calls have leaned higher, including target raises to 352 and 330, which reinforces positive sentiment.
Earnings momentum has improved, with two straight beats after a mixed stretch and the latest quarter topping estimates by 9.7%. Next-year EPS estimates still point lower than the current TTM run-rate, so shareholders should watch whether revenue growth and margin discipline keep supporting the earnings base.
The pattern is mildly positive, with more discretionary buying than selling from directors and the CFO. Most of the activity is noise from awards, exemptions, or return-related entries, but the open-market purchases from Jean Jacques Bienaime and Scott Smith outweigh the limited sales.
Profitability is strong for a biotech: gross margin is 91.9% and net margin is 72.88%, while revenue grew 73% year over year. Cash generation is positive, but the balance sheet carries $871.4 million of debt against $615.8 million of cash, leaving a net debt position.
ASND stands out on margins and growth versus most biotech peers, with rare-disease commercialization supporting a premium profile. The valuation still screens rich on earnings, and the market is paying for execution rather than balance-sheet conservatism.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.58B
- P/E
- 17.39
- Fwd P/E
- 16.82
- PEG
- 0.03
- P/S
- 13.42
- P/B
- 10.83
- EV/EBITDA
- 60.38
- Div Yield
- 0.00%
- Gross Margin
- 90.61%
- Op Margin
- 18.40%
- Net Margin
- 73.69%
- ROE
- 109.18%
- ROIC
- 11.41%
Latest fiscal year · YoY change
- Revenue
- $691.71M+90.2%
- Gross Profit
- $588.53M+84.3%
- Op Income
- $-130,892,766
- Net Income
- $-219,034,140+42.1%
- EPS
- $-3.62+44.6%
- OCF Growth
- +116.9%
- FCF Growth
- +114.2%
- 52W High
- $282.15
- 52W Low
- $188.08
- 50D MA
- $242.80
- 200D MA
- $240.72
- Beta
- 0.40
- RSI (14)
- 49
- Avg Volume
- 746.91K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ascendis delivered another very strong quarter, with product revenue nearly doubling year over year as Yorvipath, Yuvivel, and Skytrofa all contributed to growth and management raised full-year operating cash flow guidance.· November 12, 2026
- Q3 product revenue was €366 million, up 89% year over year and up €51 million sequentially, driven by all three marketed products.
- Yorvipath remained the main growth engine, with €291 million of revenue, up 103% year over year and up €39 million from Q2.
- Yuvivel revenue was €16 million in its first full U.S. quarter, while Skytrofa revenue was €59 million and management called its performance steady.
- Operating expenses fell to €217 million from €249 million in Q2, helping reported operating profit reach €125 million and non-IFRS operating profit €156 million.
- Management raised 2026 operating cash flow guidance to at least €600 million and said it ended Q3 with €964 million in cash.
Ascendis reported Q3 2026 total product revenue of €366 million, up 89% year over year and up €51 million sequentially. Yorvipath revenue was €291 million, up 103% year over year and up €39 million from Q2; Skytrofa revenue was €59 million, up €4 million sequentially; and Yuvivel revenue was €16 million, doubling from €8 million in Q2. Operating expenses were €217 million, down from €249 million in Q2; reported operating profit was €125 million and non-IFRS operating profit was €156 million, representing a 42% margin. Cash flow from operating activities was €189 million in Q3, and full-year 2026 operating cash flow is now expected to be at least €600 million. The company ended Q3 with €964 million in cash and said it repurchased 2 million shares year to date for about $460 million, including an additional $273 million after quarter-end.
Jan Moller Mikkelsen framed the quarter as evidence that Ascendis is becoming a “leading global biopharma company,” with three approved products driving both revenue and long-term sustainability. He emphasized three growth pillars: continued growth in existing indications, label expansion across the portfolio, and new products from the TransCon platform, while reiterating the goal of more than €5 billion in annual product revenue by 2030. His tone was confident and expansive, especially around global commercialization, a new therapeutic area, and the company’s ability to build multiple future blockbusters internally.
Scott Smith focused on the financial transformation underway, pointing to €366 million of Q3 product revenue, €217 million of operating expenses, and €125 million of reported operating profit. He highlighted the strength of cash generation, noting €189 million of operating cash flow in the quarter and a raised 2026 outlook of at least €600 million. He also discussed capital allocation, saying Ascendis ended Q3 with €964 million in cash and has repurchased about 2 million shares for approximately $460 million year to date, including $273 million after September 30.
Analysts pressed management on the new therapeutic area, Yorvipath prescription trends, buybacks, Yuvivel competition, operating leverage, and the achondroplasia combination program. Management said the new therapeutic area disclosure will come in the coming year and that the company wants to build it with at least 2 to 3 products, mostly through internal development but potentially with some in-licensing. On Yorvipath, management said there was no trend break in the U.S. and that ex-U.S. growth is slower but should accelerate as more countries become fully commercialized; they reiterated more than 1,000 new patients per quarter in the U.S. For the achondroplasia combination study, Jan Moller Mikkelsen said the trial was redesigned after strong regulatory feedback so that each arm could show the contribution of each component.
The bull case is that Ascendis is showing strong commercial execution across all three marketed products, led by rapid Yorvipath growth and an early Yuvivel launch that management says is tracking well. Cash generation is improving sharply, with higher operating cash flow, reduced operating expenses, and a growing cash balance, which supports continued investment and buybacks. Management also sees multiple longer-term expansion levers through label extensions, international launches, and a broader TransCon pipeline.
The main risks are that management is still heavily dependent on Yorvipath momentum and admits ex-U.S. expansion is slower and uneven because it requires country-by-country commercialization. Yuvivel remains early, with competition and future market dynamics still uncertain, and management said it could not meaningfully address a competitor’s numbers. The company is also still investing in multiple pipeline programs, including a redesigned combination trial that was delayed by regulatory feedback, so execution risk remains meaningful.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 65.60M
- Float Shares
- 65.56M
of shares held by institutions
334 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ASND, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 10.28M | 0 |
| T. Rowe Price Investment Management, Inc. | 6.75M | ▲ 592.80K |
| Westfield Capital Management Co LP | 5.13M | ▲ 326.76K |
| Avoro Capital Advisors LLC | 5.11M | ▲ 48.61K |
| Jupiter Topco LLC | 3.65M | ▲ 3.65M |
| Fmr LLC | 3.45M | ▼ 100.08K |
| Blackrock, Inc. | 2.28M | ▲ 72.18K |
| Artisan Partners Limited Partnership | 2.08M | ▼ 551.00K |
| Massachusetts Financial Services Co | 1.90M | ▲ 20.79K |
| Wellington Management Group Llp | 1.55M | ▼ 209.00K |
| Capital International Investors | 1.42M | ▼ 571.23K |
| American Century Companies Inc | 1.25M | ▼ 149.22K |
Held by 369 ETFs
Biggest fund positions in ASND by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG | other | 20,000 |
| Nov 17, 26 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG | sell | 20,000 |
| Nov 17, 26 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG | other | 20,000 |
| Apr 14, 26 | BIENAIME JEAN JACQUES | other | 9,160 |
| Apr 14, 26 | BIENAIME JEAN JACQUES | sell | 9,160 |
| Sep 8, 26 | Bodenhoff Mads | other | 3,000 |
| Sep 8, 26 | Bodenhoff Mads | other | 3,000 |
| Sep 8, 26 | Bodenhoff Mads | sell | 3,000 |
| Sep 2, 26 | HOLTUG LARS | sell | 236 |
| Aug 14, 26 | BIENAIME JEAN JACQUES | buy | 900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASND coverage
Recent articles, reports, and earnings notes.

Ascendis Pharma (ASND): Rare-Disease Growth Is Accelerating
Ascendis Pharma is transitioning into a commercial rare-disease platform, with Q2 2026 product revenue up 105% year over year and YORVIPATH emerging as the main growth engine. Valuation and execution risks remain, but the company’s expanding portfolio and strong launch momentum support a Buy view.

Ascendis Pharma A/S (ASND) nosedives 59.8% after-hours
Ascendis Pharma A/S (ASND) nosedives in after-hours trading after a delayed market reassessment of its Novo Nordisk rights reversion, ASBMR data, and funding needs. The sharp move reflects rising execution risk even as analysts still see upside in the company’s TransCon platform and pipeline.

Ascendis Pharma (ASND): YORVIPATH Drives Commercial Scale
Ascendis Pharma is transitioning into a scaled commercial biopharma, led by rapid YORVIPATH growth and a promising YUVIWEL launch. The stock still screens expensive, so the report lands on Hold despite strong revenue momentum.
Want a deeper read on ASND?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why You Shouldn't Forget This Biotech Despite Sell Signal
investors.com · Nov 20
Ascendis Pharma A/S $ASND Stock: Aberdeen Group plc Increases Holdings
defenseworld.net · Nov 18
Ascendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Ascendis Pharma A/S Q3 Earnings Call Highlights
marketbeat.com · Nov 12
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Ascendis Pharma Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
globenewswire.com · Nov 10
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
globenewswire.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice